Q2 FY2026 EarningsQ2 FY26 revenue of $56.7M beat consensus of $53.3M by 6.4%, driven by higher-than-expected supply sales and licensing reimbursements. Net loss of -$53.4M (EPS -$0.32) was significantly narrower than the anticipated -$63.7M loss (EPS -$0.38), benefiting from accelerated cost containment in SG&A. However, operating cash flow remains pressured at -$105.2M for H1, though this outperformed the -$248.7M consensus estimate for the quarter, reflecting improved capital efficiency amid a transition to a partnership-heavy commercial model.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Novavax(NVAX) the Revenue is 56.7 M (-76.3%), Beat estimate;the EBIT is -54.91 M (-154.3%), Beat estimate;the EPS is -0.32 (-151.6%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.06B76.30%
0.05B77.72%
+0.00B1.42%
EBITExceed expectations
-0.05B154.32%
-0.06B164.31%
+0.01B9.99%
EPSExceed expectations
-0.32151.61%
-0.3836161.87%
+0.063610.26%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf